Sanofi analyst focus on Dupixent and pipeline, shares tracked against Big Pharma peers

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 13:19.

Sanofi (FR0000120578) remains a core European pharma name on Euronext Paris as analysts reassess its balance of Dupixent growth, obesity ambitions and patent risks. Recent research updates compare the stock closely with U.S.-listed peers Eli Lilly and Novo Nordisk, according to market commentary.

What recent research highlights

In a June 2026 overview, Jefferies reiterated a Buy stance on Sanofi, citing sustained double-digit growth for asthma and dermatitis drug Dupixent and a solid late-stage pipeline, as reported in a recent Reuters round-up on European drugmakers. The brokerage contrasted Sanofi’s valuation with higher multiples at Novo Nordisk and Eli Lilly.

Goldman Sachs has kept a constructive medium-term view on Sanofi, pointing to improving margins and cost discipline alongside targeted investment in immunology and vaccines, according to a June analyst summary on large-cap pharma names. This stance reflects confidence in the company’s ability to convert R&D spend into commercially relevant launches over the next several years.

Consensus and valuation picture

On MarketScreener, analysts classify Sanofi largely as Buy or Hold, with an average 12-month price target implying a moderate upside from current levels and positioning the shares at a discount to the European pharma peer group on forward earnings multiples. The consensus also embeds expectations of continued high-single-digit to low-double-digit earnings growth over the medium term, supported by Dupixent and vaccines.

Data compiled by Yahoo Finance show that the NASDAQ-listed Sanofi ADR (ticker SNY) carries a market capitalization of around 100 billion U.S. dollars and trades near 11 to 12 times forward earnings, compared with materially higher multiples for Eli Lilly and Novo Nordisk in the obesity segment. This relative discount is a recurring theme in broker discussions of Sanofi’s risk-reward profile.

The product engine behind Sanofi

Sanofi generates a substantial share of its revenue from Dupixent, a monoclonal antibody for atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis, which it co-develops with Regeneron. The group also operates sizeable franchises in vaccines, rare diseases and diabetes, providing diversified cash flows across therapeutic areas.

Where the stock trades today

The Sanofi shares (FR0000120578) most recently traded on Euronext Paris at around 90 euros, while the NASDAQ-listed ADR under ticker SNY closed near 41.80 U.S. dollars on 2026-06-22.

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. All data are based on publicly available sources believed to be reliable but cannot be guaranteed.